Hallux Valgus Pipeline Insights, 2019 Report - Overview of Therapeutic Pipeline Activity - ResearchAndMarkets.com

The "Hallux Valgus - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

A detailed picture of the Hallux Valgus pipeline landscape is provided which includes the disease overview and Hallux Valgus treatment guidelines.

The assessment part of the report embraces, in depth Hallux Valgus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hallux Valgus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Hallux Valgus Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Hallux Valgus targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Hallux Valgus pipeline report covers 8+ companies. Some of the key players include Ipsen (Botulinum toxin A) etc.

Hallux Valgus Analytical Perspective

In-depth Hallux Valgus Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Scope of the report

• The Hallux Valgus report provides an overview of therapeutic pipeline activity for Hallux Valgus across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Hallux Valgus therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Hallux Valgus Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Hallux Valgus
  
  

Key Topics Covered:

1. Report Introduction

2. Hallux Valgus (Bunion)

2.1. Hallux Valgus Disease Overview

2.2. Hallux Valgus History

2.3. Hallux Valgus Symptoms

2.4. Hallux Valgus Causes

2.5. Hallux Valgus Pathophysiology

2.6. Hallux Valgus Diagnosis

2.6.1. Diagnostic Guidelines

3. Hallux Valgus Current Treatment Patterns

3.1. Treatment Guidelines

4. Hallux Valgus - An Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Hallux Valgus companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Hallux Valgus Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis

4.1.2.2. Hallux Valgus Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono/Combination)

4.2.3. Assessment by Route of Administration

4.2.4. Assessment by Molecule Type

4.2.5. Assessment by MOA

5. Hallux Valgus Pipeline Therapeutics

5.1. Late Stage Products (Phase-III)

5.1.1. Comparative Analysis

5.2. Mid Stage Products (Phase-II)

5.3. Early Stage Products (Phase-I)

5.4. Pre-clinical and Discovery Stage Products

5.5. Inactive Products

6. Hallux Valgus -Products Analysis

6.1. Product Profiles

6.1.1. Botulinum toxin A- Ipsen

6.1.1.1. Product Description

6.1.1.1.1. Product Overview

6.1.1.1.2. Mechanism of Action

6.1.1.2. Research and Development

6.1.1.2.1. Clinical Studies

6.1.1.2.1.1. Detailed Study Description

6.1.1.2.1.2. Study Results

6.1.1.2.1.3. Clinical Trials: Tabular View

6.1.1.3. Product Development Activities

6.1.1.3.1. Tabulated Product Summary

6.1.1.3.1.1. General Description Table

7. Recent Technologies

8. Hallux Valgus Key Companies

8.1. Ipsen

8.2. Concentric Analgesics

8.3. Taiwan Liposome Company

8.4. Javelin Pharmaceuticals

8.5. Janssen Research & Development, LLC

8.6. Pfizer

8.7. Pacira Pharmaceuticals, Inc

8.8. Grunenthal GmbH

9. Hallux Valgus Key Products

9.1. Botulinum toxin A

9.2. CA-008

9.3. TLC590

9.4. Intranasal Morphine (MNS075)

9.5. Tapentadol

9.6. Valdecoxib

9.7. SKY0402

9.8. GRT6005

10. Dormant and Discontinued Products

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. Hallux Valgus - Unmet Needs

12. Hallux Valgus - Future Perspectives

13. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ell32g

View source version on businesswire.com: https://www.businesswire.com/news/home/20191021005448/en/